BMI View: Israel will continue to be targeted by multinational drugmakers as a destination for innovative
drug sales; however, their relative success will be limited by funding constraints towards the country's
health services basket and the lack of transparency with new drug inclusions. An uptick in economic growth
and an increase to government funding supports our moderate growth outlook for Israel's pharmaceuticals
and healthcare sectors over the coming years.
Headline Expenditure Projections
- Pharmaceuticals: ILS7.82bn (USD2.01bn) in 2015 to ILS8.15bn (USD2.11bn) in 2016; +4.2% in local
currency terms and +4.6% in US dollar terms. Forecast in line with Q316.
- Healthcare: ILS88.95bn (USD22.90bn) in 2015 to ILS93.61bn (USD24.19bn) in 2016; +5.2% in local
currency terms and +5.6% in US dollar terms. Forecast downgraded from Q316.